NCT05151133 is a Phase 1 clinical trial of Low dose UCMSCs in Allergic Rhinitis, sponsored by Yantai Yuhuangding Hospital.

Who is sponsoring NCT05151133?

NCT05151133 is sponsored by Yantai Yuhuangding Hospital.

What drugs are being tested in NCT05151133?

Interventions in NCT05151133: Low dose UCMSCs, Moderate dose UCMSCs, High dose UCMSCs.

What condition does NCT05151133 study?

NCT05151133 studies Allergic Rhinitis.

Is NCT05151133 still recruiting?

NCT05151133 is currently status unknown. Last updated 28 March 2023.

Last reviewed 2023-03-28 · How we verify

NCT05151133

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Allergic Rhinitis Therapy by Stem Cells

Status unknown Phase 1 Last updated 28 March 2023

What this trial tests

Phase 1 trial testing Low dose UCMSCs in Allergic Rhinitis in 18 participants. Status unknown.

Timeline

13 June 2022

Primary endpoint
15 December 2024

15 December 2024

Quick facts

Lead sponsor	Yantai Yuhuangding Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	single
Primary purpose	treatment
Enrollment	18
Start date	13 June 2022
Primary completion	15 December 2024
Estimated completion	15 December 2024
Sites	1 location across China

Drugs / interventions tested

Low dose UCMSCs — full drug profile →
Moderate dose UCMSCs — full drug profile →
High dose UCMSCs — full drug profile →

Conditions studied

Allergic Rhinitis — all drugs for Allergic Rhinitis →

Sponsor

Yantai Yuhuangding Hospital

Who can join

Adults 18 to 60, any sex, with Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators is now carrying out a clinical study of Umbilical cord Mesenchymal Stem Cells (UCMSCs) in the treatment of Allergic rhinitis (AR). UCMSCs is known to its multilineage differentiation potential, strong proliferation ability, low immunogenicity, convenient material acquisition, and fewer restrictions on ethical and moral issues. The investigators hope to find a novel, minimally invasive, effective and simple treatment for the large number of patients with persistent moderate to severe AR.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

[Research advances of mesenchymal stem cell in allergic rhinitis].
Li W, Wang Y, Cheng F, Qi X, et al · · 2024 · cited 1× · PMID 38686485 · DOI 10.13201/j.issn.2096-7993.2024.05.018
Modular mastery of inflammation: umbilical cord mesenchymal stem cells as a therapeutic frontier.
Yin L, Sun CY, Chen GL, Xiang Z, et al · · 2025 · PMID 41488628 · DOI 10.3389/fimmu.2025.1721947

Verify or expand the search:

Other recruiting trials for Allergic Rhinitis

Currently open trials in the same condition.

NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
NCT07455968 — Free Diving Breathing Training in Allergic Rhinitis · NA · active not recruiting
NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis · NA · recruiting

Other Yantai Yuhuangding Hospital trials

Trials by the same sponsor.

NCT07054242 — A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvan · Phase 2 · not yet recruiting
NCT06499818 — CPVI Alone Versus CPVI Plus Low-Voltage Areas Ablation During SR Versus CPVI Plus Low-Voltage Areas Ablation During AF f · NA · not yet recruiting
NCT05800756 — Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer · Phase 2 · unknown
NCT05155657 — Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells · Phase 1 · unknown
NCT06388005 — The Application of Emotion Release Technology in Anxiety Patients Before Daytime Thyroid Surgery · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05151133 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yantai Yuhuangding Hospital
Last refreshed: 28 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05151133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing